Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06069726 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
A Phase 2 study of Recurrent Glioblastoma, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 4
- Study locations
NCT06069726 is a Phase 2 study of Recurrent Glioblastoma that is actively recruiting participants, run by Duke University. The registered enrollment target is 80 participants, above the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (18% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT06069726, a Phase 2 study of Recurrent Glioblastoma, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Conditions Studied
Interventions
- DRUG Atezolizumab
Study Locations (4)
California
- University of California, San Francisco - San Francisco
Missouri
- Saint Luke's Cancer Institute - Kansas City
North Carolina
- Duke University - Durham
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-03-21 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06069726
The ClinicalTrials.gov registry entry for NCT06069726 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (18% higher). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Atezolizumab is the first listed.
NCT06069726 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06069726 about?
NCT06069726 is a clinical study titled "A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial". This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
What is the current status of trial NCT06069726?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-03-21. Estimated completion is 2028-01-01.
What conditions does trial NCT06069726 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT06069726?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT06069726?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06069726 being conducted?
This trial has 4 study locations across California, Missouri, North Carolina, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 2
-
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan in Recurrent Glioblastoma
RECRUITING · Phase 2
-
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.